Stay up to date

To receive more information on Trulance,
please enter your information below.

To complete your registration, we ask that you take a moment to read the below information to better understand how Salix Pharmaceuticals uses the information you provided us. When you finish reading, please confirm your age. Then click SIGN UP to complete your registration.


Salix Pharmaceuticals respects the importance of your privacy and understands that your health is a very personal and sensitive subject. Salix Pharmaceuticals wants you to understand how it will use the information you provide on this registration page. By confirming your age, you are indicating that you want to learn more about this service and receive promotional or non-promotional updates via email or mail from Salix Pharmaceuticals or its partners about products, support services, or other special opportunities that Salix Pharmaceuticals or its partners believe may be interesting to you. You also understand that you may opt out of receiving any future communications from Salix Pharmaceuticals or its partners by clicking the "unsubscribe" link within any email you receive, by calling 1-800-321-4576, or by sending us a letter containing your full contact information (eg, name, email address, phone) to 200 South Jefferson Road, Whippany, NJ 07981.


To better understand how Salix Pharmaceuticals values your privacy and what other information may be collected from you while you use this service, please see our Privacy Policy.

To complete your registration, we ask that you take a moment to read the below information to better understand how Salix Pharmaceuticals uses the information you provided us. When you finish reading, please confirm your age. Then click SIGN UP to complete your registration.


Salix Pharmaceuticals respects the importance of your privacy and understands that your health is a very personal and sensitive subject. Salix Pharmaceuticals wants you to understand how it will use the information you provide on this registration page. By confirming your age, you are indicating that you want to learn more about this service and receive promotional or non-promotional updates via email or mail from Salix Pharmaceuticals or its partners about products, support services, or other special opportunities that Salix Pharmaceuticals or its partners believe may be interesting to you. You also understand that you may opt out of receiving any future communications from Salix Pharmaceuticals or its partners by clicking the "unsubscribe" link within any email you receive, by calling 1-800-321-4576, or by sending us a letter containing your full contact information (eg, name, email address, phone) to 200 South Jefferson Road, Whippany, NJ 07981.


To better understand how Salix Pharmaceuticals values your privacy and what other information may be collected from you while you use this service, please see our Privacy Policy.

All personal information will be kept confidential and will not be shared with any parties other than Salix Pharmaceuticals and its designated partners. Click here to view our full Privacy Policy.

Show More
Indication

Trulance (plecanatide) 3 mg tablets is indicated in adults for the treatment of Chronic Idiopathic Constipation (CIC) and Irritable Bowel Syndrome with Constipation (IBS-C).

IMPORTANT SAFETY INFORMATION

WARNING: RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS
Trulance® is contraindicated in patients less than 6 years of age; in nonclinical studies in young juvenile mice administration of a single oral dose of plecanatide caused deaths due to dehydration. Use of Trulance should be avoided in patients 6 years to less than 18 years of age. The safety and efficacy of Trulance have not been established in pediatric patients less than 18 years of age.

 

Contraindications
  • Trulance is contraindicated in patients less than 6 years of age due to the risk of serious dehydration.
  • Trulance is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction.
Warnings and Precautions
Risk of Serious Dehydration in Pediatric Patients
  • Trulance is contraindicated in patients less than 6 years of age. The safety and effectiveness of Trulance in patients less than 18 years of age have not been established. In young juvenile mice (human age equivalent of approximately 1 month to less than 2 years), plecanatide increased fluid secretion as a consequence of stimulation of guanylate cyclase-C (GC-C), resulting in mortality in some mice within the first 24 hours, apparently due to dehydration. Due to increased intestinal expression of GC-C, patients less than 6 years of age may be more likely than older patients to develop severe diarrhea and its potentially serious consequences.
  • Use of Trulance should be avoided in patients 6 years to less than 18 years of age. Although there were no deaths in older juvenile mice, given the deaths in young mice and the lack of clinical safety and efficacy data in pediatric patients, use of Trulance should be avoided in patients 6 years to less than 18 years of age.
Diarrhea
  • Diarrhea was the most common adverse reaction in the four placebo-controlled clinical trials for CIC and IBS-C. Severe diarrhea was reported in 0.6% of Trulance-treated CIC patients, and in 1% of Trulance-treated IBS-C patients.
  • If severe diarrhea occurs, the health care provider should suspend dosing and rehydrate the patient.
Adverse Reactions
  • In the two combined CIC clinical trials, the most common adverse reaction in Trulance-treated patients (incidence ≥2% and greater than in the placebo group) was diarrhea (5% vs 1% placebo).
  • In the two combined IBS-C clinical trials, the most common adverse reaction in Trulance-treated patients (incidence ≥2% and greater than in the placebo group) was diarrhea (4.3% vs 1% placebo).

Please also see the full Prescribing Information, including BOXED Warning, for additional risk information.